Stock Events

Stock Events

Krystal Biotech 

$321.42
82
+$0.00+0%Thursday 00:00

Statistics

Day High
321.42
Day Low
321.42
52W High
375.92
52W Low
274.68
Volume
1
Avg. Volume
-
Mkt Cap
9.51B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 2Expected
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Q3 2026
1.09
1.61
2.14
2.66
Expected EPS
1.789
Actual EPS
2.05

Financials

52.64%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
389.13MRevenue
204.83MNet Income

Analyst Ratings

$394.83Average Price Target
The highest estimate is ⁦441.00⁩.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow KRYS.BOATS. It's not an investment recommendation.
NVIDIA
26
NVDA
Microsoft
24
MSFT
Amazon
20
AMZN
Alphabet
20
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abeona Therapeutics
ABEO
Mkt Cap248.75M
Abeona Therapeutics focuses on developing gene and cell therapies for life-threatening diseases, similar to Krystal Biotech's gene therapy approach.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including gene therapies.
Pfizer
PFE
Mkt Cap173.95B
Pfizer, through its acquisition of Bamboo Therapeutics, has ventured into gene therapy, making it a competitor with its vast resources.
Vertex Pharmaceuticals
VRTX
Mkt Cap141.65B
Vertex Pharmaceuticals, with its CRISPR and gene editing ventures, represents a broader competitor in the genetic treatment landscape.
Novartis
NVS
Mkt Cap303.67B
Novartis has made significant investments in gene therapy, including the acquisition of AveXis, positioning it as a major player in the field.

About

Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
Show More
CEO
ISIN
US5011471027

Listings

MI
IT
1KRYS.MI
SA
BR
K1YS34.SA
XETRA
DE
4KB.XETRA
STU
DE
4KB.STU

0 Comments

Share your thoughts

FAQs

What is Krystal Biotech stock price today?▼
The current price of KRYS.BOATS is $321.42 USD — it has increased by +0% in the past 24 hours. Watch Krystal Biotech stock price performance more closely on the chart.
What is Krystal Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boats exchange Krystal Biotech stocks are traded under the ticker KRYS.BOATS.
What is Krystal Biotech market cap?▼
Today Krystal Biotech has the market capitalization of 9.51B
When is the next Krystal Biotech earnings date?▼
Krystal Biotech is going to release the next earnings report on March 1, 2027.
What were Krystal Biotech earnings last quarter?▼
KRYS.BOATS earnings for the last quarter are 2.05 USD per share, whereas the estimation was 1.79 USD resulting in a +14.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Krystal Biotech revenue for the last year?▼
Krystal Biotech revenue for the last year amounts to 389.13M USD.
What is Krystal Biotech net income for the last year?▼
KRYS.BOATS net income for the last year is 204.83M USD.
In which sector is Krystal Biotech located?▼
Krystal Biotech operates in the Other sector.
When did Krystal Biotech complete a stock split?▼
Krystal Biotech has not had any recent stock splits.